PO.ET09.04 · 实验与分子治疗

靶向Rpn13Pru的小分子诱导乳腺癌细胞有丝分裂阻滞

Rpn13Pru targeting small molecules induce mitotic arrest in breast cancer.

海报缩略图:靶向Rpn13Pru的小分子诱导乳腺癌细胞有丝分裂阻滞
编号 5796 展板 23 时间 4/21 02:00–05:00 区域 Section 15 主讲 Santwana K C, B Pharm;PhD
分会场 Proximity-Induced Drug Discovery 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Santwana K C1, Xiuxiu Lu2, Snehal M. Gaikwad3, Venkata R. Sabbasani4, Rolf Swenson4, Beverly A. Mock3, Kylie J. Walters2, Deborah E. Citrin1

1Radiology Oncology Branch, National Cancer Institute, Bethesda, MD,2National Cancer Institute, Frederick, MD,3Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD,4Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, Bethesda, MD

摘要 Abstract

中文摘要
蛋白水解靶向嵌合体是一种异双功能分子,将目标蛋白(POI)与E3泛素连接酶连接,通过泛素-蛋白酶体系统(UPS)促进POI的泛素化和降解。XL44是一种经结构修饰的小分子,此前被鉴定为强效的hRpn13 Pru降解剂,能在骨髓瘤细胞中诱导泛素依赖性凋亡和泛素非依赖性细胞周期缺陷。近期,我们评估了另外两种更强效的衍生物XL69和XL80,它们具有相似的细胞周期阻滞机制。在此,我们评估了XL69和XL80介导的UPS功能破坏在MCF-7细胞系中的抗癌活性。用XL69和XL80处理MCF-7细胞24小时,通过MTT法测定IC 50值。对于细胞周期分析,用10 μM各化合物处理细胞24小时,通过流式细胞术分析。通过蛋白质印迹和免疫荧光显微镜评估纺锤体组装检查点(SAC)和后期促进复合物/细胞周期体(APC/C)活性。XL69和XL80的MTT法显示,在浓度高于30 μM处理时细胞毒性增加,但细胞在较低浓度下即表现出快速脱附。脱附的漂浮细胞在处理后接下来的48-72小时内仍保持活力,随后死亡,并表现出核形态和细胞骨架组织的显著变化。XL69和XL80处理的MCF-7细胞在G2/M期蓄积(分别为65.7%和54.1%,对比DMSO为25.2%;p < 0.001)。此外,处理后24小时检测到磷酸化组蛋白3水平升高(分别为31.5%、32.5%,对比DMSO为10.7%,p值 < 0.01),表明存在强劲的有丝分裂阻滞。用DAPI核染色对aurora B进行的免疫荧光检测证实,处理细胞发生前中期-中期阻滞。蛋白质印迹分析显示Bub1和BubR1上调,证实有丝分裂阻滞后SAC激活。SAC的激活导致有丝分裂检查点复合物形成,随后抑制APC/C,如细胞周期蛋白B和securin的蓄积所示。此外,APC/C的抑制还阻止了aurora B激酶的降解,导致微管蛋白组装受损。免疫荧光图像显示,XL69和XL80处理导致微管蛋白组织紊乱,与微管聚合抑制剂Nocodazole类似。这些发现表明,XL69和XL80通过靶向APC/C通路诱导有丝分裂阻滞并破坏微管动力学。这些研究证明,小分子XL69和XL80在贴壁MCF-7细胞中有效诱导有丝分裂阻滞、损害微管动力学、破坏细胞附着从而导致细胞死亡。该处理导致持续的细胞周期阻滞、SAC激活、APC/C通路抑制和微管组织受损。因此,该研究凸显XL69和XL80作为靶向有丝分裂进程的有前景的抗癌药物。
查看英文原文 English abstract
Proteolysis-targeting chimeras are heterobifunctional molecules that link a protein of interest (POI) to an E3 ubiquitin ligase, promoting ubiquitylation and degradation of the POI via the ubiquitin- proteasome system (UPS). XL44 is a structurally modified small molecule previously identified as a potent hRpn13 Pru degrader, that induces ubiquitin-dependent apoptosis in myeloma cells. and ubiquitin-independent cell cycle defects. Recently, we evaluated two more potent derivatives; XL69 and XL80 with a similar cell cycle arrest mechanism. Here, we evaluated that the anticancer activity of XL69 and XL80 mediated disruption of UPS function in the MCF-7 cell line. MCF-7 cells were treated with XL69 and XL80 for 24 h and the IC 50 values were determined by MTT assay. For cell cycle analysis, cells were treated with 10 µM of each compound for 24 h and analyzed via flow cytometry. The spindle assembly checkpoint (SAC), and anaphase promoting complex/ cyclosome (APC/C) activity were assessed through western blotting and immunofluorescence microscopy. The MTT assay for XL69 and XL80 showed increased cytotoxicity at concentrations above 30 µM upon treatment but cells exhibited rapid detachment at lower concentrations. Detached, floating cells remained viable for the next 48-72 h post-treatment before cell death and exhibited marked variation in nuclear morphology and cytoskeleton organization. XL69 and XL80 treated MCF-7 cells accumulated in G2/M (65.7% and 54.1%, respectively vs DMSO- (25.2%; p < 0.001). In addition, elevated levels of phospho-histone 3 were detected 24 h post-treatment (31.5%, 32.5%, vs DMSO 10.7%, p-value <0.01) indicating robust mitotic arrest. Immunofluorescent detection of aurora B with DAPI nuclear staining confirmed prometaphase-metaphase arrest in treated cells. Western blot analysis showed upregulation of Bub1 and BubR1, confirming SAC activation post mitotic arrest. Activation of the SAC led to formation of the mitotic checkpoint complex, subsequently inhibiting the APC/C, as evidenced by the accumulation of cyclin B and securin. Furthermore, the inhibition of APC/C also prevented degradation of aurora B kinase, resulting in impaired tubulin assembly. Immunofluorescent images showed disordered organization of tubulin with XL69 and XL80 treatment, similar to Nocodazole, a microtubule polymerization inhibitor. These findings suggest that XL69 and XL80 induce mitotic arrest by targeting the APC/C pathway and disrupt microtubule dynamics. These studies demonstrate that the small molecules XL69 and XL80 effectively induce mitotic arrest, impair microtubule dynamics, disrupt cellular attachment leading to cell death in adherent MCF-7 cells. The treatment led to sustained cell cycle arrest, SAC activation, APC/C pathway inhibition and impaired microtubule organization. As such, the study highlights XL69 and XL80 as promising anti-cancer agents that target mitotic progression.
利益披露 Disclosure
S. K c, None.. X. Lu, None.. S. M. Gaikwad, None.. V. R. Sabbasani, None.. R. Swenson, None.. B. A. Mock, None.. K. J. Walters, None.. D. E. Citrin, None.

← 返回 AACR 2026 检索